144 related articles for article (PubMed ID: 29724147)
1. Characteristics of fibrinolytic disorders in acute promyelocytic leukemia.
Wang P; Zhang Y; Yang H; Hou W; Jin B; Hou J; Li H; Zhao H; Zhou J
Hematology; 2018 Dec; 23(10):756-764. PubMed ID: 29724147
[TBL] [Abstract][Full Text] [Related]
2. [Clinical study on the fibrinolytic activity in patients with acute promyelocytic leukemia].
Liu YH; Wang ZY; Zhang W; Dai L; Shen WH; Ruan CG
Zhonghua Xue Ye Xue Za Zhi; 2009 Mar; 30(3):145-9. PubMed ID: 19642359
[TBL] [Abstract][Full Text] [Related]
3. Arsenic trioxide, retinoic acid and Ara-c regulated the expression of annexin II on the surface of APL cells, a novel co-receptor for plasminogen/tissue plasminogen activator.
Zhang X; Zhou H; Wang J; Yang L; Hu Y; Shen G; Guo P; Qiao Z; Song S
Thromb Res; 2002 Apr; 106(1):63-70. PubMed ID: 12165291
[TBL] [Abstract][Full Text] [Related]
4. The expression of annexin II and its role in the fibrinolytic activity in acute promyelocytic leukemia.
Liu Y; Wang Z; Jiang M; Dai L; Zhang W; Wu D; Ruan C
Leuk Res; 2011 Jul; 35(7):879-84. PubMed ID: 21146216
[TBL] [Abstract][Full Text] [Related]
5. Effects of all-trans-retinoic acid and arsenic trioxide on the hemostatic disturbance associated with acute promyelocytic leukemia.
Zhao W; Wang H; Wang X; Wu F; Guo W; Qu B; Shen Z; Wang Z
Thromb Res; 2001 May; 102(3):197-204. PubMed ID: 11369412
[TBL] [Abstract][Full Text] [Related]
6. Addition of Arsenic Trioxide into Induction Regimens Could Not Accelerate Recovery of Abnormality of Coagulation and Fibrinolysis in Patients with Acute Promyelocytic Leukemia.
Zhang Y; Wu S; Luo D; Zhou J; Li D
PLoS One; 2016; 11(1):e0147545. PubMed ID: 26812490
[TBL] [Abstract][Full Text] [Related]
7. Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia.
Tallman MS; Lefèbvre P; Baine RM; Shoji M; Cohen I; Green D; Kwaan HC; Paietta E; Rickles FR
J Thromb Haemost; 2004 Aug; 2(8):1341-50. PubMed ID: 15304040
[TBL] [Abstract][Full Text] [Related]
8. The coagulopathy of acute promyelocytic leukaemia revisited.
Stein E; McMahon B; Kwaan H; Altman JK; Frankfurt O; Tallman MS
Best Pract Res Clin Haematol; 2009 Mar; 22(1):153-63. PubMed ID: 19285282
[TBL] [Abstract][Full Text] [Related]
9. Arsenic trioxide at conventional dosage does not aggravate hemorrhage in the first-line treatment of adult acute promyelocytic leukemia.
Cui W; Wang J; Nie RM; Zhao LL; Gao MQ; Zhu HM; Chen L; Hu J; Li JM; Shen ZX; Wang ZY; Chen SJ; Chen Z; Wang KK; Xi XD; Mi JQ
Eur J Haematol; 2018 Apr; 100(4):344-350. PubMed ID: 29266395
[TBL] [Abstract][Full Text] [Related]
10. Hemostatic abnormalities associated with acute promyelocytic leukemia and corrective effects of all-trans-retinoic acid or arsenic trioxide treatment.
Zhao W; Wang X; Guo W; Qu B; Wang H; Shen Z; Chen Z; Wang Z
Chin Med J (Engl); 2000 Mar; 113(3):236-40. PubMed ID: 11775254
[TBL] [Abstract][Full Text] [Related]
11. Coagulation disorders associated with acute promyelocytic leukemia: corrective effect of all-trans retinoic acid treatment.
Dombret H; Scrobohaci ML; Ghorra P; Zini JM; Daniel MT; Castaigne S; Degos L
Leukemia; 1993 Jan; 7(1):2-9. PubMed ID: 8418375
[TBL] [Abstract][Full Text] [Related]
12. [A study of tissue factor expression and hemostatic molecular markers in patients with acute promyelocytic leukemia].
Wu F; Wang X; Zhao W; Wang H; Shen Z
Zhonghua Nei Ke Za Zhi; 2001 Jan; 40(1):36-9. PubMed ID: 11798557
[TBL] [Abstract][Full Text] [Related]
13. Effect of all-trans retinoic acid on procoagulant and fibrinolytic activities of cultured blast cells from patients with acute promyelocytic leukemia.
De Stefano V; Teofili L; Sica S; Mastrangelo S; Di Mario A; Rutella S; Salutari P; Rumi C; d'Onofrio G; Leone G
Blood; 1995 Nov; 86(9):3535-41. PubMed ID: 7579461
[TBL] [Abstract][Full Text] [Related]
14. New insights into the pathogenesis of coagulation dysfunction in acute promyelocytic leukemia.
Tallman MS; Hakimian D; Kwaan HC; Rickles FR
Leuk Lymphoma; 1993 Sep; 11(1-2):27-36. PubMed ID: 8220153
[TBL] [Abstract][Full Text] [Related]
15. Elevated tissue plasminogen activator and reduced plasminogen activator inhibitor promote hyperfibrinolysis in trauma patients.
Cardenas JC; Matijevic N; Baer LA; Holcomb JB; Cotton BA; Wade CE
Shock; 2014 Jun; 41(6):514-21. PubMed ID: 24667610
[TBL] [Abstract][Full Text] [Related]
16. Dose-adjusted arsenic trioxide for acute promyelocytic leukaemia in chronic renal failure.
Firkin F; Roncolato F; Ho WK
Eur J Haematol; 2015 Oct; 95(4):331-5. PubMed ID: 25600167
[TBL] [Abstract][Full Text] [Related]
17. The coagulopathy in acute promyelocytic leukaemia--what have we learned in the past twenty years.
Kwaan HC; Cull EH
Best Pract Res Clin Haematol; 2014 Mar; 27(1):11-8. PubMed ID: 24907013
[TBL] [Abstract][Full Text] [Related]
18. The unique hemostatic dysfunction in acute promyelocytic leukemia.
Kwaan HC
Semin Thromb Hemost; 2014 Apr; 40(3):332-6. PubMed ID: 24590422
[TBL] [Abstract][Full Text] [Related]
19. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.
Leonardi A; Brun P; Sartori MT; Cortivo R; Dedominicis C; Saggiorato G; Abatangelo G; Secchi AG
Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1364-70. PubMed ID: 15790903
[TBL] [Abstract][Full Text] [Related]
20. The influence of joint application of arsenic trioxide and daunorubicin on primary acute promyelocytic leukaemia cells and apoptosis and blood coagulation of cell strain.
Zhang X; Qin N; Chen X; Guo S
Pak J Pharm Sci; 2015 May; 28(3 Suppl):1075-8. PubMed ID: 26051726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
